The rating assignment was supported by a number of factors, including Barnabas’ growing liquidity. As of Sept. 30, the system had unrestricted cash and investments of $1.14 billion, or 159.5 days cash on hand.
The rating assignment was also supported by Barnabas’ considerable market presence, strong margins and acquisition of the Jersey City (N.J.) Medical Center.
Fitch analysts expect Barnabas Health to use the expected increase in cash flow to continue to grow liquidity and strengthen its balance sheet metrics. Additionally, Fitch predicts the system will have to implement its strong management practices to the Jersey City Medical Center to grow profitability.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
